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KRAS mutations hinder therapeutic efficacy of epidermal growth factor receptor (EGFR)-specific monoclonal antibodies
cetuximab and panitumumab-based immunotherapy of EGFR+ cancers. Although cetuximab inhibits KRAS-mutated cancer cell
growth in vitro by natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), KRAS-mutated colorectal
carcinoma (CRC) cells escape NK cell immunosurveillance in vivo. To overcome this limitation, we used cetuximab and
panitumumab to redirect Fcγ chimeric receptor (CR) T cells against KRAS-mutated HCT116 colorectal cancer (CRC) cells.
We compared four polymorphic Fcγ-CR constructs including CD16158F-CR, CD16158V-CR, CD32131H-CR, and CD32131R-CR transduced
into T cells by retroviral vectors. Percentages of transduced T cells expressing CD32131H-CR (83.5  9.5) and CD32131R-CR
(77.7  13.2) were significantly higher than those expressing with CD16158F-CR (30.3  10.2) and CD16158V-CR (51.7  13.7)
(p < 0.003). CD32131R-CR T cells specifically bound soluble cetuximab and panitumumab. However, only CD16158V-CR T cells
released high levels of interferon gamma (IFNγ = 1,145.5 pg/ml 16.5 pg/ml, p < 0.001) and tumor necrosis factor alpha
(TNFα = 614 pg/ml  21 pg/ml, p < 0.001) upon incubation with cetuximab-opsonized HCT116 cells. Moreover, only CD16158V-CR
T cells combined with cetuximab killed HCT116 cells and A549 KRAS-mutated cells in vitro. CD16158V-CR T cells also effectively
controlled subcutaneous growth of HCT116 cells in CB17-SCID mice in vivo. Thus, CD16158V-CR T cells combined with cetuximab
represent useful reagents to develop innovative EGFR+KRAS-mutated CRC immunotherapies.
Introduction
Epidermal growth factor receptor (EGFR) is overexpressed in
several solid tumors.1 Upon binding by epidermal growth
factor (EGF), EGFR triggers a series of signaling pathways
supporting invasion and metastasis.1 The important role of
EGFR in promoting cancer progression has provided the
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rationale for the development of EGFR-targeted monoclonal
antibody (mAb)-based treatments.2
EGFR-specific cetuximab is a chimeric IgG1 mAb preven-
ting EGFR dimerization by stimulating its internalization and
degradation. EGFR-specific panitumumab is a human IgG2
mAb interfering with EGF binding to its receptor. Cancer cells
incubated with cetuximab or panitumumab undergo cell cycle
arrest and apoptosis.2 However, a variety of EGFR+ cancer
cells, including colorectal carcinoma (CRC) cells, are insensi-
tive to EGFR-specific mAbs since they carry RAS gene
mutation(s) downstream of EGFR. Because of these muta-
tions, cancer cells can bypass antitumor activities of both
cetuximab and panitumumab. Lack of sensitivity of KRAS-
mutated CRC cells to EGFR-specific mAb has serious clinical
consequences since in these cases both cetuximab and pan-
itumumab have either no effect on tumor growth or worsen
CRC clinical course.3,4
Increasing evidence suggests that this limitation can be
overcome, at least for cetuximab, by taking advantage of its
ability to mediate ADCC since EGFR+ cells, opsonized with
cetuximab, undergo ADCC by activating the CD16 receptor
expressed on natural killer (NK) cells.5 Nevertheless, cancer
progression in patients is not arrested.3,4
Failure to control cancer growth might be due to the ability
of cancer cells to escape recognition by innate and adaptive
immune cells. In patients with cancer, both NK cells, the
major ADCC effector cells, and T cells are characterized by a
variety of functional defects.6,7 However, T-cell infiltration
into the tumor microenvironment is more frequently detect-
able and is associated with favorable prognosis.8–11 In con-
trast, NK cell infiltration in solid tumors is rare and usually
devoid of prognostic significance.12
To restore the sensitivity of KRAS-mutated cancer cells to
EGFR-specific mAbs, we investigated different strategies
based on the generation of extracellular CD16-(chimeric
receptor) CR linked to intracellular signaling and activating
molecules.13–17 Because of NK cell limitations,6–10,12,18 we
decided to use T cells, as effectors, since they easily infiltrate
the tumor microenvironment and effectively protect hosts
from cancer progression.19 Selected CD16-CR constructs
were transduced into T cells to redirect them by EGFR-
specific mAbs toward EGFR+ cancer cells.
Other than NK cells, myeloid cells also mediate effector
functions including proinflammatory cytokine production20,21
and cytotoxic activity including ADCC.20,22 Unlike NK cells,
myeloid cells have the exclusive property to recognize Fc frag-
ments of IgG2 antibodies complexed with the corresponding
antigens on target cells, utilizing the Fc receptor CD32 and
triggering ADCC activation.23 Both CD16 and CD32 are poly-
morphic and their polymorphisms influence their binding to
IgG Fc fragments.24 It is still unknown whether CD32 and
CD16 polymorphisms impact the antitumor activity of Fcγ-
CR T cells against KRAS-mutated CRC cells.
The goal of this study is to compare the ability of polymor-
phic CD16-CR and CD32-CR to inhibit KRAS-mutated CRC
cell proliferation and tumor progression in vitro and in vivo.
Materials and Methods
Antibodies, reagents, and cell lines
Fluorescein isothiocyanate (FITC)-conjugated mouse anti-
human CD3 (cat. 555332), FITC-conjugated-annexin V (cat.
556420), phycoerythrin (PE)-conjugated mouse anti-CD16
(cat. 555407), PE-conjugated mouse anti-human CD32 (cat.
550586), propidium Iodide (PI) (cat. 556463), allophycocyanin
(APC)-conjugated mouse anti-human CD3 (cat. 555335),
mouse anti-human CD3 (cat. 555329), CD28 (cat. 555725),
CD32 (8.26) (cat. 557333), and CD16 (3g8) (cat. 556617)
were purchased from BD Bioscience (San Jose, CA).
Cetuximab (Erbitux 5 mg/ml) and panitumumab (Vectibix
20 mg/ml) were purchased from Merck Serono (Darmstadt,
Germany) and Amgen (Thousand Oaks, CA), respectively.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) was purchased from Sigma-Aldrich (Saint
Louis, MO) and GeneJuice® Transfection Reagent (Novagen)
from Millipore (Burlington, MA). Human recombinant
interleukin-7 (IL-7) and interleukin-15 (IL-15) were pur-
chased from PeproTech (London, UK) and Lipofectamine
2000 from Life Technologies (Carlsbad, CA). Retronectin
(Recombinant Human Fibronectin) was purchased from
Takara Bio (Saint-Germain-en-Laye, France). Dulbecco’s
modified Eagle’s medium, Iscove’s modified Dulbecco’s medium,
RPMI 1640 medium, fetal bovine serum (FBS), L-glutamine,
and penicillin/streptomycin were purchased from Thermo
Fisher Scientific (Waltham, MA). Complete media (CM) were
supplemented with 10% FBS, 2 mM L-glutamine, 0.1 mg/ml
streptomycin, and 100 U/ml penicillin. Mycoplasma-free, KRAS-
mutated HCT116 cells25 (RRID:CVCL_0291) were maintained
in RPMI 1640, CM. Mycoplasma-free, KRAS-mutated,
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added to adherent cells. Incubation was prolonged for 3 hr at
37C. Supernatants were then removed and 100 μl of dimethyl
sulfoxide were added to each well. Absorbance was measured
at 570 nm.
Cytokine release
Twofold dilutions of a Fcγ-CR T cell suspension (1x105/
100 μl/well) were added to 96-well plates in triplicates. Then,
EGFR+, KRAS-mutated HCT116 cells (2 × 104/100 μl/well) were
added at a 5:1 E:T ratio in the presence or absence of 3 μg/ml
cetuximab or panitumumab. Supernatants were collected after
48 hr incubation at 37C and IFNγ, and TNFα levels were mea-
sured by ELISA (Thermo Fisher Scientific, Waltham, MA).
Flow cytometry and cytotoxicity assay
Fcγ-CR expression levels on engineered T cells were assessed
by flow cytometry upon incubation for 30 min at 4C with
FITC-conjugated mouse anti-human CD3, PE-conjugated
mouse anti-human CD32, or PE-conjugated mouse anti-
human CD16 mAbs.
To assess cytotoxic potential of transduced lymphocytes,
KRAS-mutated HCT116 cells or A549 cells (0.12 × 106) were
incubated overnight at 37C in 5% CO2 in the presence or
absence of CD16158V-CR T cells (0.6 × 106), with or without
anti-EGFR mAbs (10 μg/ml) while nontransduced T cells
(0.6 × 106) were used as control. Cultures were then harvested
and cells were stained with FITC-Annexin V, APC-conjugated
anti-CD3, and PI. HCT116 and A549 cells were identified by
gates posted on CD3 negative and FSC-Hhigh cells. The cells
were analyzed by a 2-laser BD FACSCalibur (Becton Dickin-
son, S. Jose, CA) flow cytometer. Results were evaluated utiliz-
ing the Tree Star Inc. FlowJo software.
Xenograft mouse model
In vivo experiments were performed in accordance with the
guidelines and regulations of the European Directive 2010/63/
EU. The Italian Ministry of Health approved animal handling
and procedures (authorization code: 186/2016-PR). Antitumor
activity of CD16158V-CR T cells with or without cetuximab
was assessed using 8-week-old male CB17-SCID mice (CB17/
lcr-PrkdcSCID/lcrlcoCrl, Charles River Laboratories, Lecco,
Italy, Cat. CRL:236, RRID: IMSR CRL:236), 12-18 g body
weight, engrafted with KRAS-mutated HCT116 CRC cells.
Mice were housed in temperature-controlled rooms with
12 hr light/dark cycle and free access to sterile water and
autoclaved standard chow diet (4RF25; Mucedola, Milan,
Italy). Endogenous NK cell activity was suppressed by intra-
peritoneal injection of 20 μl rabbit anti-asialo-GM1 antibody
(Wako, Chemicals, Richmond, VA, Cat. 986-10001). Mice
received anti-asialo-GM1 antibody on days −3, 0, +14, and
+21 since tumor cell engraftment. On day 0, mice were
grafted subcutaneously in the right flank, with 1 × 106
HCT116 cells and then randomly separated into four groups
(5 mice per group). Group 1 received only HCT116, group
non-small-cell-lung cancer cell line, A549 (RRID:CVCL_0023) 
was kindly provided by Dr. Antonio Rossi (Institute of Transla-
tional Pharmacology, CNR, Rome, Italy). The cells were 
authenticated on November 21, 2018, by PCR-single-locus-
technology (Eurofins, Ebersberg, Germany). The cells were kept 
in culture for a maximum of four to eight passages.
Fcγ chimeric receptors
Generation of CD16158F-CD8α-CD28-CD3ζ CR has previ-
ously been described.16 The extracellular region of CD32A131R 
was amplified by reverse-transcriptase polymerase chain 
reaction (RT-PCR) from RNA extracted from peripheral 
blood mononuclear cells (PBMCs) utilizing the following 
primers: forward 50-GAGAATTCACCATGACTATGGAG 
ACCCAAATG-30 and reverse 50-CGTACGCCCCATTG 
GTGAAGAGCTGCC-30 (Thermo Fisher Scientific, Waltham, 
MA). PCR product was fused by restriction enzyme-compatible
ends with the CD8α-CD28-CD3ζ domain contained in the 
pcDNA3.1/V5-His TOPO TA (Invitrogen, Carlsbad, CA). 
CD16158F-CR and CD32131R-CR were subcloned into NcoI 
and MluI sites of the SFG retroviral vector. CD16158V and 
CD32A131H were assembled by using synthetic oligonucleo-
tides. Fragments were separately inserted into SFG vector 
and sequenced by GeneArt Gene Synthesis team (Invitrogen-
Thermo Fisher Scientific, Regensburg, Germany).
Retrovirus production and T-cell transduction
Retroviral supernatants were obtained by transient transfec-
tion of 293T cells, with Peg-Pam plasmid encoding the 
Moloney murine leukemia virus gag and pol genes, and RDF 
plasmid encoding the RD114 envelope and the CD32131R-, 
CD32131H-, CD16158F-, or CD16158V-CR SFG retroviral vectors 
using the GeneJuice reagent. Forty-eight and 72 hr post-
transfection, retrovirus-containing supernatants were harvested, 
filtered, snap frozen, and stored at −80C until use. To generate 
Fcγ-CR T cells, PBMCs (0.5 × 106 PBMCs/ml) were cultured 
for 3 days in nontissue culture treated 24-well plates precoated
with 1 μg/ml anti-CD3 and 1 μg/ml anti-CD28 mAbs in the 
presence of 10 ng/ml IL-7 and 5 ng/ml IL-15. Viral superna-
tants were placed on retronectin-coated nontissue culture-
treated 24-well plates and spun for 1.5 hr at 2000g. Activated T 
cells were seeded into retrovirus-loaded plates, spun for 100, 
and incubated for 72 hr at 37C in 5% CO2 atmosphere. After 
transduction, T cells were expanded in RPMI 1640 CM sup-
plemented with 10 ng/ml IL-7 and 5 ng/ml IL-15.
In vitro tumor cell viability assays
The antitumor activity of Fcγ-CR T cells in vitro was evalu-
ated by MTT assays. Tumor target cells (7 × 103/well) were 
seeded in 96-well plates, and Fcγ-CR T cells (35 × 103/well) 
were added in the presence or absence of (3 μg/ml) cetuximab 
or panitumumab. Following a 48–72 hr incubation at 37C, 
nonadherent T cells were removed and 100 μl/well of fresh 
medium supplemented with 20 μl of MTT (5 mg/ml) were
2 received cetuximab (150 μg), group 3 HCT116 and
CD16158V-CR T cells, and group 4 HCT116 CD16158V-CR T
cells and cetuximab (150 μg). Effector cells were administered
at a 5:1 E:T ratio. Tumor volumes were measured every
3 days with caliper and calculated using the formula: TV
(cm3) = 4/3pr3, where r = (length + width)/4. Mice were
sacrificed when tumor volume reached 2 cm3.
Statistical analysis
Results were analyzed by paired-t-test, Mann–Whitney test,
and two-way analysis of variance (ANOVA) followed by
Bonferroni’s multiple-comparison correction, as necessary.
Disease-free survival (DFS) was evaluated by log-rank-
(Mantel-Cox) test. Differences were considered significant
with p-values <0.05.
Data availability
The data supporting the findings of this study are available
from the corresponding author upon reasonable request.
Results and Discussion
To enhance antitumor potential of EGFR-specific mAbs, we
generated polymorphic CD16 and CD32-CR vectors (Fig. 1a).
We successfully expressed all indicated Fcγ-CR into trans-
duced T cells (Fig. 1b). However, T cell transduction of
CD32131H-CR (83.5%  9.5%) and CD32131R-CR (77.7%  13.2%)
was significantly more effective than that of CD16158V-CR
(51.7%  13.7%) and CD16158F-CR (30.3%  10.2%) (p < 0.003
Fig. 1c). Considering that all vectors are packaged using the same
methodology and viral titers are similar, these results may sug-
gest that in human T lymphocytes polymorphic CD32-CR are
more stably expressed as compared to polymorphic CD16-CR,
although underlying mechanism(s) remain to be explored.
Notably however, Cheeseman et al. provided evidence that
hematopoietic cells tend to express CD32 more efficiently than
CD16 on their surfaces.26
CD16-CR has also been produced in other laboratories,
whereas, to the best of our knowledge, CD32-CR has not.
CD16 and CD32 binding affinity for IgG is known to be
influenced by their polymorphisms. The presence of valine
instead of phenylalanine at position 158 of CD16 (CD16158V)
and the presence of histidine instead of arginine at position
131 of CD32 (CD32131H) enhance the IgG binding affinity of
these receptors.24,27 Notably, CD16158V has preferentially been
utilized for in vitro and in vivo studies.13–15,28
To evaluate Fcγ-CR T cell antibody-binding capacity, poly-
morphic CD32-CR and CD16-CR T cells were incubated with
cetuximab or panitumumab, for 30 min, at 4C. CD32131R-CR
T cells efficiently bound both cetuximab and panitumumab,
whereas CD32131H-CR T cells only displayed a minimal bind-
ing for panitumumab (Fig. 1d, lower panel). In contrast,
CD16158V-CR T cells and CD16158F-CR T cells failed to bind
both cetuximab and panitumumab (Fig. 1d, upper panels).
Binding of cetuximab and panitumumab to CD32-CR T cells
was highly specific and promptly inhibited in the presence of
Fc receptor blocking reagent (FcR BR) (Fig. 1d, lower panels).
Although in our study, neither CD16158V-CR nor
CD16158F-CR showed significant binding affinity for soluble
cetuximab (IgG1) or panitumumab (IgG2), Kudo et al.15
previously reported that CD16158V-CR has a significantly
higher affinity for rituximab (IgG1) than that of CD16158F-CR.
Notably, however, in accord with our data, Snyder et al. observed
that NK92 cells expressing the high-affinity CD16A176V variant
do not bind trastuzumab (IgG1).29 A possible explanation of
these discrepancies might reside in structural differences in
the stimulatory domains of the transduced chimeras. Never-
theless, our data clearly indicate that multivalent presenta-
tion of immobilized cetuximab, but not panitumumab,
effectively induces CD16158V-CR stimulation, leading to sig-
nificant enhancement of IFNγ and TNFα release, thereby
suggesting that CD16-CR T successfully bind immobilized
cetuximab (Fig. 1e).
We next asked whether polymorphic Fcγ-CR T cells recog-
nize KRAS-mutated HCT116 cells opsonized with EGFR-
specific mAb and affect their viability. Transduced and non-
transduced T cells were incubated, for 72 hr, at 37C with
KRAS-mutated HCT116 cells with or without cetuximab or
panitumumab. Production of IFNγ and TNFα was measured in
culture supernatants. Only CD16158V-CR T cells, combined
with cetuximab but not panitumumab, produced levels of both
IFNγ (1,145.5  16.5 pg/ml) and TNFα (614  21 pg/ml) sig-
nificantly higher than those released by the other Fcγ-CR T
cells or nontransduced T cells (Fig. 2a).
Then, we tested whether polymorphic Fcγ-CR engineered
T cells could impair the viability of KRAS-mutated HCT116
cell opsonized with cetuximab or panitumumab, by utilizing an
ADCC mechanism. Figure 2b shows that KRAS-mutated
HCT116 cell viability, expressed as optical density (OD), was
significantly reduced following a 48 hr incubation at 37C with
CD16158V-CR T cells and cetuximab (0.67-OD  0.03-OD) as
compared to nontransduced T cells (1.5-OD  0.03-OD).
In contrast, no change in viability was detected when
cetuximab was replaced with panitumumab. Both polymor-
phic CD32-CR T cells and CD16158F-CR T cells with or
without anti-EGFR mAbs, failed to impair KRAS-mutated
HCT116 cell viability.
To further validate the cytotoxic activity of CD16158V-CR,
HCT116, and A549 cells, also characterized by KRAS muta-
tions and EGFR expression were incubated overnight at 37C
in 5% CO2, with or without CD16
158V-CR T cells, in the pres-
ence or absence of cetuximab. In these assays, we observed
that cetuximab-opsonized HCT116 and A549 cells clearly
undergo apoptosis and necrosis in the presence of CD16158V-
CR T (Fig. 2c). These data indicate that efficient recognition
of cetuximab-opsonized cancer cells by CD16158V-CR T cells
leads to the activation of effector functions including pro-
duction of proinflammatory cytokines and impairment of
KRAS-mutated HCT116 and A549 cell viability. Therefore,
Since these data challenged the effector potential of CD16158F-
and CD32-CR T cells, we tested them in redirected ADCC
assays, using, as targets, KRAS-mutated HCT116 cells
Figure 1. Molecular structure and functional features of Fcγ-CRs. Panel A shows a schematic representation of the gene constructs encoding
the indicated Fcγ-CRs. The extracellular domain of high- and low-affinity CD32-CRs and CD16-CRs incorporate the transmembrane CD8α and
CD28/CD3ζ chain. Panel B reports a representative experiment showing the expression of Fcγ-CRs on the surface of T cells 48 hr after
retroviral transduction. Percentages of cells expressing the transgenes are shown in the quadrants. Panel C shows cumulative percentages of
positive T lymphocytes for each Fcγ-CR 48 hr following viral infection of cells from five healthy donors. ****p < 0.0001, **p < 0.003. Panel D
shows the binding of soluble cetuximab and panitumumab on the surface of Fcγ-CR T cells. T lymphocytes expressing each CD16-CR (upper
panel) and CD32-CR (lower panel) polymorphisms were incubated with 10 μg/ml of either cetuximab or panitumumab for 30 min at 4C with
or without FcR BR. The cells were then washed and stained with a FITC-conjugated mouse anti-human IgG antibody. Binding of cetuximab and
panitumumab was then evaluated by flow cytometry. FcR BR: Fc receptor blocking reagent. Panel E shows ELISA assays of IFNγ and TNFα
release in the culture supernatants, of CD16158V-CR T cells cultured, in 24-well plates, for 72 hr at 37C, in the presence or absence of
10 μg/ml of the following mAbs: soluble or immobilized cetuximab and soluble or immobilized panitumumab while an anti-CD3 mAb
(10 μg/ml) was utilized as a positive control. ***p < 0.0007, ****p < 0.0001.
CD16158V-CR T cells restore the ability of cetuximab to tar-
get KRAS-mutated HCT116 CRC cells by an immune-
mediated mechanism in vitro.
stably transfected with CD32. Although to different extents,
all CR-engineered T cells, at different E:T ratios, signifi-
cantly reduced the viability of FcγR+HCT116 cells in the
presence of 3g8 (anti-CD16) or 8.26 (anti-CD32) mAb
(Fig. 2d). These data indicate that all engineered T cells are
fully competent effector cells.
Thus, although transgenic CD32 binds soluble mAbs
and is able to provide a cytotoxic signal, CD32-CR T cells
are unable to produce proinflammatory cytokines in co-
culturing with opsonized KRAS-mutated HCT116 and to
impair their viability. Therefore, soluble mAb binding and
redirected killing do not appear to represent effective surro-
gate assays to test the ability of transduced T cells to elicit mAb-
mediated effector functions targeting tumor cells. Notably,
affinity of IgG1 cetuximab for CD32 is low and panitumumab
mediates ADCC only in the presence of myeloid cells.23
Figure 2. Legend on next page.
The in vivo antitumor potential of CD16158V-CR T cells was
then assessed. Transduced cell ability to impair KRAS-mutated
HCT116 viability was tested prior to their administration to
experimental animals. CD16158V-CR T cells were incubated at
37C with target cells and cetuximab or panitumumab, while
nontransduced T cells were used as a negative control. Follow-
ing 72 hr incubation, KRAS-mutated HCT116 viability was
assessed by the MTT assay. Data reported in Figure 3a confirm
that co-culture with CD16158V-CR T cells, in combination with
cetuximab, significantly affects HCT116 cell viability. Instead,
CD16158V-CR T alone or together with panitumumab or non-
transduced T cells were completely ineffective.
We then engrafted CB17-SCID mice subcutaneously with
KRAS-mutated HCT116 cells. One hour later, CD16158V-CR
T cells, with or without cetuximab, were injected in proximity
to the injection site of HCT116 cells. Figure 3b shows volumes
of HCT116 tumors on day 64 postinjection. CD16158V-CR T
cells combined with cetuximab significantly protected mice
from tumor growth. DFS of treated animals is reported in
Figure 3c. Interestingly, tumor growth was also significantly
delayed in the group of mice receiving CD16158V-CR only.
SCID mice are characterized by an efficient NK cell com-
partment. Therefore, in vivo antitumor effects might be
attributed to resident NK cells rather than to exogenously
administered CD16158V-CR T cells. However, no antitumor
activity was detectable upon cetuximab administration in the
absence of CD16158V-CR T cells. Moreover, although
cetuximab can mediate ADCC in vitro,5 it has no impact on
progression of KRAS-mutated colorectal cancers.3,4 Further-
more, our experiments were performed upon repeated
administration of anti-asialo-GM1Abs, resulting in NK cell
depletion.
Figure 3. CD16158V-CR T cells in combination with cetuximab protect CB17 SCID mice from subcutaneous growth of KRAS-mutated
HCT116 cancer cells. Panel (a) shows HCT116 cells incubated for 72 hr, at 37C, in the presence or absence of CD16158V-CR T cells at
the indicated E:T ratios with or without cetuximab (C) or panitumumab (P) both at the concentration of 3 μg/ml. Nontransduced T cells
were used as a control. HCT116 cell viability was evaluated by MTT assay. Values are expressed as mean  SD. Data are analyzed by a
two-way ANOVA test. Panel (b) shows four groups of CB17 SCID mice (N = 5 per group) injected with HCT116 cells (1 × 106)
subcutaneously, in the right flank. Following HCT116 injection, three groups of mice were injected, in the area adjacent to HCT116
injection, with 150 μg of cetuximab (group 2), 5 × 106 CD16158V-CR T cells (group 3), and 5 × 106 CD16158V-CR T cells plus 150 μg of
cetuximab (group 4). HCT116 cell growth was then monitored. Left panel shows a scatterplot analysis of tumor volumes resulting from
subcutaneous injection of KRAS-mutated HCT116 cells 64-days postinjection. Right panel shows DFS analysis, as evaluated by the log-
rank (Mantel-Cox) test. *p < 0.02, **p < 0.001.
Figure 2. Recognition of HCT116 CRC cells by CD16158V-CR T cells in combination with cetuximab leads to proinflammatory cytokine
production and HCT116 cell elimination. Panel (a) shows IFNγ and TNFα levels in supernatants of HCT116 cells incubated for 48 hr at 37C 
with the indicated Fcγ-CR T cells in the presence or absence of cetuximab (3 μg/ml) or panitumumab (3 μg/ml), both at a E:T ratio of 5:1. 
Panel (b) shows viability, as evaluated by MTT assays of HCT116 cells incubated for 48 hr at 37C with the indicated Fcγ-CR T cells with or 
without cetuximab or panitumumab at a E:T cell ratio of 5:1. C, cetuximab; P, panitumumab; white bars, nontransduced T cells. Asterisks 
indicate a p-value <0.001. The figure reports cumulative data, with mean  SD values, of HCT116 cell viability obtained by using effector cells 
from five different donors in independent experiments. Panel (c) shows CD16158V-CR T cells killing of KRAS-mutated cell lines (HCT116 and 
A549) with or without cetuximab or panitumumab at an E:T ratio of 5:1. Nontransduced T cells were used as a control. After 16 hr, incubation 
cells were harvested, stained with APC-anti-CD3, FITC-annexin V and propidium iodide (PI), and analyzed by flow cytometry. Data are 
representative of five experiments independently performed. Panel (d) shows the results of redirected assays on the viability of stably
transfected CD32 + HCT116 cells, as measured by the MTT assay. Fcγ-CR T cells were incubated for 3 days, at 37C with CD32 + HCT116 in 
the presence or absence of anti-CD16 mAb (3 μg/ml) (right panel) with or without anti-CD32 mAb (3 μg/ml) (left panel) at the indicated E:T 
cell ratio. Viability of HCT116 target cells was then measured as described in the Methods section. Asterisks indicate p < 0.001.
This is the first study demonstrating the ability of
CD16158V-CR combined with cetuximab to control KRAS-
mutated cancer cell growth in vitro and in vivo. Our results,
obtained by using the same target cells, document the supe-
rior antitumor potential of CD16158V, as compared to the
other CR under investigation, despite an equivalent reverse
ADCC capacity. CD16158V-CR superiority may reflect its
optimal interaction with cetuximab Fc fragment.5
Taken together, these data contribute to a repositioning of
currently available anti-EGFR therapeutic mAbs in the treat-
ment of insensitive tumors, and pave the way toward innova-
tive immunotherapies targeting KRAS-mutated cancers.
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